Gopakumar K G, Thankamony Priyakumari, Seetharam Shwetha, P Kusumakumary
a Department of Pediatric oncology , Regional Cancer Centre , Trivandrum , Kerala , India.
Pediatr Hematol Oncol. 2017 May;34(4):206-211. doi: 10.1080/08880018.2017.1348415. Epub 2017 Sep 5.
Rasburicase is a novel drug used during the management of tumor lysis syndrome. In countries with limited resources, it is frequently given at a lower dose and only for the treatment of established tumor lysis syndrome and not as prophylaxis. A retrospective study was conducted in the department of pediatric oncology at a tertiary referral oncology center in south India to analyze the use of rasburicase over the past 3 years. Data of all the 18 children (< 14 years of age) who were given rasburicase for the management of hyperuricemia were collected and analyzed. With a mean rasburicase dose of 0.085 mg/kg, hyperuricemia was managed efficiently without the need for a hemodialysis in 16 children (88.8 %). The fall in mean serum uric acid levels after the administration of a single dose of rasburicase at 4, 24, and 48 hours was 31.18 %, 64.8 %, and 74.5 %, respectively. Rasburicase efficiently decreases the uric acid levels to a normal level within a short period. In resource-limited settings, rasburicase at a lower dose is a promising option for managing hyperuricemia in the event of a tumor lysis syndrome.
拉布立酶是一种用于治疗肿瘤溶解综合征的新型药物。在资源有限的国家，该药通常以较低剂量给药，且仅用于治疗已确诊的肿瘤溶解综合征，而非用于预防。在印度南部一家三级转诊肿瘤中心的儿科肿瘤科室进行了一项回顾性研究，以分析过去3年拉布立酶的使用情况。收集并分析了所有18名接受拉布立酶治疗高尿酸血症的儿童（<14岁）的数据。拉布立酶的平均剂量为0.085mg/kg，16名儿童（88.8%）的高尿酸血症得到有效控制，无需进行血液透析。单次注射拉布立酶后4小时、24小时和48小时，平均血清尿酸水平分别下降31.18%、64.8%和74.5%。拉布立酶能在短时间内有效将尿酸水平降至正常。在资源有限的情况下，较低剂量的拉布立酶是治疗肿瘤溶解综合征时控制高尿酸血症的一个有前景的选择。
